{
    "title": "RL34584",
    "content": "The Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits discrimination based on genetic information by health insurers and employers. The Human Genome Project (HGP) provided resources for determining the causes and potential cures for common diseases like diabetes, heart disease, Parkinson's disease, bipolar disorder, and asthma. Scientists hoped the HGP data would help identify genetic factors influencing various diseases. The Human Genome Project aimed to identify genetic factors influencing diseases, leading to the Genetic Information Nondiscrimination Act (GINA) in 2008 to prevent discrimination based on genetic information by health insurers and employers. GINA was enacted to address concerns about potential misuse of genetic information, which could deter individuals from seeking genetic testing and participating in research. The report discusses genetic research, GINA's statutory provisions, HHS and EEOC regulations, and the potential of genomic research to reduce disease burden. Clinical genetic tests are increasing, with insurers starting to cover them as evidence of their validity and utility. Precision medicine is a focus of recent genetic research. Precision medicine, a new term for personalized medicine, involves providing healthcare based on individual characteristics, including genomic information. The National Institutes of Health (NIH) is prioritizing precision medicine through the Precision Medicine Initiative, which includes a national research cohort of 1 million volunteers for research on novel therapeutics and prevention strategies. The Human Genome Project (HGP) laid the foundation for precision medicine. The completion of the Human Genome Project (HGP) offers a unique opportunity to understand genetic factors in health and disease, leading to advancements in prevention, diagnosis, and treatment through genomics-based approaches. This includes identifying genes and pathways, predicting disease susceptibility and drug response more accurately, early illness detection, and developing new therapeutic strategies. The completion of the Human Genome Project led to advancements in prevention, diagnosis, and treatment through genetic research. Concerns about the misuse of genetic information were addressed by setting aside funds for ethical, social, and legal analysis. Dr. Collins highlighted the importance of understanding the clinical and public health implications of genetic research. Dr. Collins emphasized the potential misuse of genetic information for discrimination in employment and health insurance, leading to public fear and hindering genetic testing uptake. The SACGHS found that a majority of Americans are concerned about access to their genetic information, with many fearing discrimination by insurers. Public forums sponsored by SACGHS and SACGT gathered perspectives on genetic discrimination from various stakeholders. Comments were received from a diverse range of individuals, including patients, health professionals, and industry representatives, revealing cases of genetic discrimination. SACGT expressed concerns to the Secretary of HHS about the misuse of genetic information by third parties, such as insurers and employers, leading to fears of discrimination and reluctance to undergo genetic testing. The joint report by various government departments highlighted concerns about genetic discrimination in the workplace, even for healthy individuals. Misuse of genetic information could have broad intergenerational effects. The National Council on Disability (NCD) published a position paper in 2002 on genetic discrimination, stating that recent advances in genetic research have increased the potential for discrimination. They highlighted that genetic discrimination undermines genetic research and testing purposes, and current laws were insufficient to protect individuals. Title I of GINA extended HIPAA protections against discrimination by health plans and insurers. At the time of GINA's enactment, HIPAA prohibited group health plans from using genetic information for eligibility or setting premiums. Protections applied to individuals but not to the whole group or group premiums. The HIPAA law did not prevent entire groups from being charged more, and genetic information could be used to set premiums for individual health insurance policies. HIPAA also allowed group health plans to exclude coverage for specific conditions and impose lifetime caps on benefits. Additionally, at the time of GINA's enactment, HIPAA did not prohibit group health plans from requiring genetic information or testing. The Americans with Disabilities Act (ADA) prohibits discrimination based on disability in various areas. The ADA defines disability as a physical or mental impairment that limits major life activities. Genetic traits are not explicitly mentioned in the ADA. During congressional debate, genetic traits were discussed in relation to the ADA. Prior to GINA's enactment, there were no specific judicial decisions on genetic predisposition and the ADA, but cases brought by the EEOC resulted in settlements. The ADA's definition of \"disability\" was interpreted to include genetic information related to illness. EEOC guidance cited legislative history in defining disability for compliance. The EEOC examined the definition of disability under the ADA, concluding that discrimination based on genetic information related to illness is prohibited. However, Supreme Court decisions have narrowed this interpretation. EEOC Commissioner Paul Miller stated that the ADA can be interpreted to prohibit employment discrimination based on genetic information, but its protections are limited and uncertain. Commissioner Miller noted that the ADA may not fully protect workers from genetic discrimination, as it does not prevent employers from requesting genetic information or conducting genetic tests if job-related. The uncertainty surrounding the ADA's coverage of genetic discrimination has increased due to a lack of reported cases and Supreme Court decisions on disability definitions. The ADA Amendments Act broadened the definition of disability to provide broader coverage, but did not specifically address genetic discrimination. Even if the ADA covers genetic discrimination, GINA's protections are more targeted towards genetic information. Executive Order 13145 prohibits discrimination against federal employees based on protected genetic information. The Genetic Information Nondiscrimination Act (GINA) protects genetic information of individuals and their family members from discrimination in health insurance and employment. GINA prohibits discrimination based on genetic tests, family medical history, or occurrence of diseases in family members. The statute is divided into three titles, addressing health insurance, employment, and miscellaneous provisions. GINA's definition of genetic information is a key provision. The Genetic Information Nondiscrimination Act (GINA) protects genetic information from discrimination in health insurance and employment. Discussions focused on defining genetic information, including exclusions like basic demographic data and family history. The definition relies on terms like \"genetic test\" and \"family member\" to delineate the law's protections. Both Title I and Title II contain a definition of genetic information. The Genetic Information Nondiscrimination Act (GINA) protects genetic information from discrimination in health insurance and employment. The term 'genetic information' includes genetic tests, family members' genetic tests, and disease manifestation in family members. Exclusions are information about sex or age. Regulations have been issued implementing GINA, excluding certain sections related to medigap and privacy. The Department of Health and Human Services issued regulations to implement the Genetic Information Nondiscrimination Act (GINA), including provisions related to medigap and privacy. The regulations clarify that race and ethnicity, if not derived from genetic tests, are not considered genetic information. The definition of genetic test is crucial in determining the impact of these regulations. The definition of genetic test in the Genetic Information Nondiscrimination Act (GINA) is crucial in determining the impact of the regulations. Title I exempts genetic tests related to manifested diseases, while Title II defines genetic tests as analyses of DNA, RNA, chromosomes, proteins, or metabolites detecting genotypes, mutations, or chromosomal changes. Title II of the Genetic Information Nondiscrimination Act (GINA) includes Section 210, which allows for the use, acquisition, or disclosure of medical information that is not genetic information about a manifested disease, disorder, or pathological condition of an employee or member. The interim final regulations provide specific examples of genetic and non-genetic tests to illustrate the definition's scope. The EEOC's final regulations also include specific examples of genetic tests and tests or procedures that are not genetic. Title II of GINA includes Section 210, which allows for the use, acquisition, or disclosure of medical information that is not genetic information about a manifested disease, disorder, or pathological condition of an employee or member. The regulations provide examples of genetic tests, such as BRCA1 or BRCA2 variants for breast cancer predisposition, and non-genetic tests like cholesterol levels or drug presence tests. Testing for alcohol or drugs is not considered genetic unless it determines a genetic predisposition. GINA strengthens HIPAA nondiscrimination provisions through amendments to ERISA and PHSA. The Employee Retirement Income Security Act of 1974 (ERISA), the Public Health Service Act (PHSA), and the Internal Revenue Code (IRC), as well as the Social Security Act (SSA), bring group plans under ERISA, group and individual plans under PHSA, Church Plans under IRC, and Medigap plans under SSA under the jurisdiction of the law. The HHS interim final regulations implement Sections 101, 102, and 103 of Title I of GINA, prohibiting health insurers from using genetic information to adjust premiums or deny coverage. GINA prohibits health plans, insurers, and issuers from adjusting premiums or denying coverage based on genetic information. It also prohibits the use of genetic information for underwriting purposes and treats genetic information as a preexisting condition. The Genetic Information Nondiscrimination Act (GINA) prohibits health plans, insurers, and issuers from using genetic information for underwriting purposes or denying coverage based on genetic information. It also treats genetic information as a preexisting condition and prohibits the request or requirement of genetic testing for individuals or their family members by health plans and insurers. The Genetic Information Nondiscrimination Act (GINA) prohibits insurers from using genetic information for underwriting purposes. It also prohibits the request or requirement of genetic testing for individuals or their family members. The Genetic Information Nondiscrimination Act (GINA) prohibits insurers from using genetic information for underwriting purposes, including the manifestation of a disease in an individual or their family member. Insurers cannot use this information to establish premiums or conditions of eligibility. Additionally, insurers cannot use the manifestation of a disease in one individual to determine the risk of other family members covered under the same policy. However, insurers are allowed to use genetic test results for determining payment. The Genetic Information Nondiscrimination Act (GINA) prohibits insurers from using genetic information for underwriting purposes. Insurers can use genetic test results to determine payment, but only the minimum information necessary. Insurers may condition payment on genetic test results for treatments dependent on genetic makeup. Payment denial for treatment without genetic test results is allowed. Using genetic information for payment determination is not a violation of GINA. The Genetic Information Nondiscrimination Act (GINA) prohibits insurers from using genetic information for underwriting purposes. The HIPAA Privacy Rule was revised to reflect genetic information as health information, prohibiting its use for underwriting by covered entities. Final regulations were issued by the Department of Health and Human Services to implement this rule. The HIPAA Privacy Rule prohibits the use of genetic information for underwriting by covered entities, including various types of health plans. Despite GINA only mentioning group health plans, the prohibition extends to all entities defined as \"health plans\" except for issuers of long-term care policies. Under the final rule, health plans are prohibited from using genetic information for underwriting purposes, even if authorized by the individual. Penalties can be imposed for noncompliance with GINA's nondiscrimination requirements, with a penalty of $100 per day per beneficiary during periods of noncompliance. GINA establishes penalties for noncompliance with Title I provisions, with a minimum penalty of $2,500 for willful neglect. There are limitations to the penalties imposed by the Secretary, including exceptions for lack of knowledge or timely corrections. The total penalty for unintentional failures is capped at $500,000 or 10% of the plan sponsor's previous year's expenses. The Secretary has waiver authority for excessive penalties. The HHS interim final regulations do not address enforcement authorities for genetic information under GINA. GINA prohibits genetic information discrimination in employment and restricts employers from requesting or using genetic information in employment decisions. EEOC regulations for Title II align with GINA's provisions. The Genetic Information Nondiscrimination Act (GINA) prohibits the use of genetic information in employment decisions, including hiring, firing, job assignments, and promotions. It applies to employees and applicants in the private sector, federal and state governments, and congressional employees. Employers, employment agencies, labor organizations, and training programs are covered by the law. The Genetic Information Nondiscrimination Act (GINA) prohibits employers, employment agencies, labor unions, or training programs from requesting or acquiring genetic information about employees, individuals, union members, or their family members. There are exceptions to this rule, but even if an exception applies, genetic information cannot be used in a way that violates nondiscrimination or confidentiality requirements. One exception is when these entities inadvertently obtain family medical history through casual conversations with workers. The Genetic Information Nondiscrimination Act (GINA) prohibits entities from requesting genetic information, with exceptions such as obtaining family medical history through casual conversations. Another exception is for health or genetic services offered as part of a wellness program, with strict authorization and confidentiality requirements. The EEOC regulations allow inducements to encourage participation in wellness programs, but genetic information cannot be used as an inducement. An example provided is offering $150 for completing a health risk assessment with genetic questions, as long as the reward is given regardless of answering those questions. The EEOC regulations allow inducements for wellness program participation, but genetic information cannot be used as an inducement. The regulations clarify that wellness program questions must be clear to avoid violating GINA. They do not limit rights under the ADA, other civil rights laws, or HIPAA. The ACA also addresses wellness programs, but interaction with GINA provisions is unclear. The EEOC has sued a company for violating GINA with its wellness program. The court noted uncertainty regarding how the ACA, ADA, and GINA interact. The EEOC regulations track statutory provisions, including exceptions for genetic information acquisition. One exception is for information necessary for certification procedures under family and medical leave laws. Another exception is for the inadvertent acquisition of genetic information through the purchase of publicly available documents. The EEOC's regulations include electronic media as potential sources of genetic information, with key criteria being access permission and source categorization. Exceptions apply to genetic information acquisition, such as through the purchase of publicly available documents. The fifth exception to genetic information acquisition regulations applies when genetic monitoring is for biological effects of toxic substances in the workplace. Prior authorization, compliance with regulations, and informing individuals of monitoring results are required for this exception to apply. Employers and training programs can request genetic information from employees for DNA analysis for law enforcement purposes, but only for quality control and sample contamination detection. Genetic information must be kept confidential and maintained separately as a medical record. Employment agencies, labor unions, and joint labor-management committees are prohibited from disclosing genetic information, except in specific circumstances such as written requests from employees, court orders, or for research purposes in compliance with regulations. The Genetic Information Nondiscrimination Act (GINA) allows disclosure of genetic information in specific circumstances, such as court orders, compliance with Title II of GINA, certification provisions of the Family and Medical Leave Act, or to public health agencies for contagious diseases. GINA also addresses the relationship between confidentiality provisions and the HIPAA Privacy Rule. The EEOC final regulations address concerns raised by commenters regarding genetic information under GINA. Existing genetic information in personnel files before GINA's effective date does not violate the law, but disclosing it to a third party does. Remedies and enforcement mechanisms under GINA are similar to those under Title VII of the Civil Rights Act of 1964. Individuals who believe they are victims of employment discrimination based on genetic information can file a complaint with the EEOC for enforcement. If the EEOC does not take action or reach a settlement, the individual can file a lawsuit in federal court. The EEOC received 88,778 complaints of employment discrimination in FY2014, with only 333 based on GINA. Limited cases have reached federal court, but the EEOC has pursued cases against employers independently. Under Title VII, employees can file disparate impact claims for discrimination based on race, color, religion, sex, or national origin. GINA does not allow disparate impact claims but establishes a commission to review genetic science. Section 209 of GINA clarifies the relationship between Title I and Title II, ensuring no limitation on individual rights under other statutes. Title II of GINA clarifies that it does not limit individual rights under other statutes and establishes a \"firewall\" between Titles I and II. It also specifies exceptions, such as not applying to the Armed Forces repository of specimen samples or affecting workers' compensation laws. Section 209 of GINA clarifies that it does not limit individual rights under other statutes and establishes exceptions regarding workplace safety and health laws. It also includes genetic information of fetuses and embryos in its provisions. The activity of a group health plan or health insurance issuer offering group health insurance coverage authorized by Title I, ERISA, the Public Health Service Act, and the Internal Revenue Code is clarified by Section 210 of GINA. It does not cover medical information that is not genetic information about a manifested disease, disorder, or pathological condition. The final EEOC regulations elaborate on this, stating that the acquisition, use, and disclosure of medical information not genetic information about a manifested disease is subject to limitations under the ADA. The EEOC and HHS rules define \"manifestation\" as a disease that can be diagnosed by a healthcare professional. The ADA Amendments Act expanded disability coverage, reducing the number of individuals not covered by either law. The definitions of \"manifestation\" in the EEOC and HHS rules have been expanded to include individuals with a diagnosed genetic disease that is not yet substantially limiting. This broadens the protections under both titles by excluding those with a manifested disease diagnosed primarily based on genetic information. Such sums as necessary are authorized to be appropriated for this purpose. The Genetic Information Nondiscrimination Act (GINA) allows necessary appropriations and includes a severability provision. Title III also amended child labor protections. Educating the public about GINA is crucial as awareness remains low. A 2008 survey showed limited knowledge of genetic privacy laws, with only 16% awareness. A 2010 study found that only 16% of Americans are aware of laws protecting privacy, with 77% unsure if they are protected. The law's scope is limited to health insurance and employment, not covering long term care insurance, life insurance, short-term disability insurance, or long-term disability insurance. Clear education is needed to avoid confusion about genetic discrimination protections. Title I of GINA extends privacy and confidentiality protections to certain health plans under the HIPAA Privacy Rule, prohibiting the use of genetic information for underwriting. This extension does not apply to long-term care insurance issuers due to a lack of evidence on the impact of genetic information use in underwriting. GINA does not necessarily protect against discrimination in health insurance and employment. Title I of GINA extends privacy protections to health plans under HIPAA, prohibiting genetic information use for underwriting. However, GINA does not necessarily protect against discrimination in health insurance and employment. Specific provisions clarify that health insurers and employers can use manifested disease information for certain purposes without violating GINA. The ACA reforms private health insurance, limiting insurers' ability to discriminate based on health status. The ACA addresses employer wellness programs and the information they may collect from employees, intersecting with GINA which prohibits genetic information use for underwriting but does not protect against discrimination in health insurance and employment."
}